secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIORA THERAPEUTICS, INC. (—)
CIK:        0001580063
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060453
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biora reports Q1 net loss $4.2M, completes BT-600 dosing, results expected late Q2
--------------------------------------------------------------------------------

- Net loss $4.2M ($0.14/share) vs $17.4M ($1.59) in Q1 2023; operating expenses $16.1M.
- BT-600 Phase 1 trial fully dosed; SAD data showed colon delivery and lower plasma levels than oral tofacitinib.
- BioJet platform animal studies demonstrate >15% bioavailability; partnering process targeting mid-2024.
- Capital raised $19.8M new investment since Dec 2023, reduced $80M notes; $6M direct placement closed April 2024.
- Topline BT-600 data expected late June 2024; NaviCap device data presented at DDW May 19.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1580063/000095017024060453/0000950170-24-060453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1580063/000095017024060453/bior-20240515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer